Test Price
2,800 AED✅ Home Collection Available
FGFRL1 Gene Radioulnar Synostosis Genetic Test in UAE – Comprehensive NGS Analysis
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by a Consultant Medical Genetics specialist.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
DHA Regulatory Compliance: Fully licensed under Dubai Healthcare City regulations; all patient data protected under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Test Overview & Methodology
The FGFRL1 gene evaluation by Next‑Generation Sequencing (NGS) comprehensively identifies pathogenic variants linked to radioulnar synostosis and overlapping skeletal, dermatological, and immunological phenotypes. The analysis covers all coding exons, splice sites, and detects copy number variants (CNVs) with greater than 99.9% sensitivity, enabling precise molecular diagnosis and early therapeutic intervention planning.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Mutation Detection | All coding exons, splice sites, CNVs >99.9% sensitivity | Single‑variant or hotspot only; limited resolution |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Utility | Comprehensive gene‑wide analysis; future re‑analysis possible | Reflex to NGS often required if negative |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics specialist, I want every family to know that this test provides a molecular blueprint—not a prophecy. The results must be interpreted alongside clinical and radiological findings by a multidisciplinary team. Early detection empowers you to make informed decisions about interventions, physiotherapy, and family planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Clinical Advisory – Precautions Before Testing
Genetic test results do not replace ongoing clinical management. Do not discontinue prescribed medication without consulting your physician. All results should be correlated with clinical, radiological, and family history data for accurate interpretation.
- Patients with acute febrile illness or active systemic infection should defer blood collection until full recovery.
- Known coagulopathy or platelet disorder requires physician clearance for venipuncture.
🚨 Emergency Red Flags – Seek Immediate Care
- Sudden inability to move the affected arm, severe pain, or visible deformity—seek emergency care immediately.
- Signs of compartment syndrome (severe swelling, numbness, pallor)—rush to nearest hospital.
Patient FAQ & Clinical Guidance
1. What does the FGFRL1 gene test detect?
The test identifies single-nucleotide variants, small insertions/deletions, and copy-number changes across the entire FGFRL1 gene associated with radioulnar synostosis, craniosynostosis-like features, and immune-related skin disorders. This comprehensive analysis provides a definitive molecular diagnosis to guide clinical management.
2. How is the sample collected for this genetic test?
A certified phlebotomist collects 2–4 mL of whole blood in an EDTA tube or a dried blood spot on an FTA card during a home or clinic visit. The sample is transported under strict temperature-controlled cold-chain conditions to preserve DNA stability and ensure optimal sequencing results.
3. What is the expected turnaround time for results?
The standard turnaround is 3–4 weeks from the date the sample arrives at the laboratory. This allows thorough sequencing, bioinformatics analysis, and clinical validation by our Consultant Medical Genetics specialist before the final report is issued.
4. Who will interpret my test results?
Your results are reviewed and interpreted by a DHA-licensed Consultant Medical Genetics specialist (Lina Osama Zaki Quteineh, DHA ID: 9294403) who provides a detailed clinical report with recommendations for further management and genetic counseling.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Security
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, access-controlled, and handled exclusively within the UAE jurisdiction. Clinical safety and patient consent procedures adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE is DHA-licensed (Facility No. 1143) and operates under the regulatory oversight of the Dubai Healthcare City Authority – Regulatory (DHCR). Your genetic information remains confidential and is never shared without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | FGFRL1 Gene Radioulnar Synostosis Sequencing (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Coding Exons & Splice Sites |
| ICD-10-CM Code | Q74.0 |
| LOINC Code | 94222-3 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians